Pinnacle West (PNW) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $52 price target. Company has below-average earnings and dividend growth.
Ventas (VTR) downgraded at Jefferies to Hold from Buy, Jefferies said. $66 price target. Fiscal cliff looms.
STOCK COMMENTS / EPS CHANGESApache (APA) estimates, target cut at Guggenheim. Shares of APA now seen reaching $111, according to Guggenheim. Estimates also reduced, given increased fleet downtime. Buy rating.
Baker Hughes (BHI) estimates cut at Dahlman through 2013, Dahlman Rose said. Company is leveraged to slower growth in North America. Buy rating and $50 price target.
Peabody Energy (BTU) numbers raised at Citigroup. Shares of BTU now seen reaching $33, Citigroup said. Estimates also increased on improving cost and capex management. Buy rating.Peabody Energy numbers boosted at Credit Suisse. Shares of BTU now seen reaching $33, according to Credit Suisse. Estimates also upped, as the company continues to execute well. Outperform rating. Caterpillar (CAT) estimates, target cut at Credit Suisse. Shares of CAT now seen reaching $108, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Outperform rating. Capital One (COF) numbers raised at Guggenheim. Shares of COF now seen reaching $72, according to Guggenheim. Estimates also increased, as the company is realizing higher margins. Buy rating. Cognizant Technology (CTSH) target raised at Oppenhiemer to $80, Oppenheimer said. Raising target ahead of quarterly results. Outperform rating. Freeport-McMoRan (FCX) numbers cut at UBS. Shares of FCX now seen reaching $47, UBS said. Estimates also lowered as Grasberg guidance marginally lower. Buy rating. Freeport-McMoran numbers reduced at JP Morgan. Shares of FCX now seen reaching $63, according to JP Morgan. Estimates also cut, given lower realized gold volumes. Overweight rating. Forest Laboratories (FRX) numbers cut at Morgan Stanley. FRX estimates were reduced through 2013, Morgan Stanley said. Company is seeing slower sales growth. Equal-weight rating and new $35 price target. Health Management (HMA) numbers lowered at Credit Suisse. Shares of HMA now seen reaching $10, according to Credit Suisse. Estimates also cut, given weaker volumes and rising costs. Outperform rating.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV